These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11168439)

  • 1. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up.
    Vendemiale G; Grattagliano I; Portincasa P; Serviddio G; Palasciamo G; Altomare E
    Eur J Clin Invest; 2001 Jan; 31(1):54-63. PubMed ID: 11168439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study.
    Tsuji K; Yamasaki K; Yamanishi M; Kawakami M; Shirahama S
    J Gastroenterol Hepatol; 2001 May; 16(5):536-40. PubMed ID: 11350550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.
    Persico M; Persico E; Suozzo R; Conte S; De Seta M; Coppola L; Palmentieri B; Sasso FC; Torella R
    Gastroenterology; 2000 Apr; 118(4):760-4. PubMed ID: 10734027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.
    Uto H; Kurogi J; Takahama Y; Kusumoto K; Hayashi K; Ido A; Kohara M; Stuver SO; Moriuchi A; Hasegawa S; Oketani M; Tsubouchi H
    J Gastroenterol; 2007 Aug; 42(8):673-80. PubMed ID: 17701131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress].
    Acar A; Görenek L; Aydin A; Eyigün CP; Eken A; Sayal A; Pahsa A
    Mikrobiyol Bul; 2009 Jul; 43(3):411-23. PubMed ID: 19795616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
    Pár A; Roth E; Miseta A; Hegedüs G; Pár G; Hunyady B; Vincze A
    Orv Hetil; 2009 Jan; 150(2):73-9. PubMed ID: 19103558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.
    Montalto G; Zignego AL; Ruggeri MI; Giannini C; Soresi M; Monti M; Carroccio A; Careccia G; Di Martino D; Giannelli F
    Dig Dis Sci; 1997 Aug; 42(8):1703-7. PubMed ID: 9286237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.
    Sangiovanni A; Morales R; Spinzi G; Rumi M; Casiraghi A; Ceriani R; Colombo E; Fossati M; Prada A; Tavani E; Minoli G
    Hepatology; 1998 Mar; 27(3):853-6. PubMed ID: 9500717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).
    Puoti C; Castellacci R; Montagnese F; Zaltron S; Stornaiuolo G; Bergami N; Bellis L; Precone DF; Corvisieri P; Puoti M; Minola E; Gaeta GB
    J Hepatol; 2002 Jul; 37(1):117-23. PubMed ID: 12076870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels.
    Carreño V; Pardo M; López-Alcorocho JM; Rodríguez-Iñigo E; Bartolomé J; Castillo I
    J Infect Dis; 2006 Jul; 194(1):53-60. PubMed ID: 16741882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.
    Puoti C; Magrini A; Stati T; Rigato P; Montagnese F; Rossi P; Aldegheri L; Resta S
    Hepatology; 1997 Dec; 26(6):1393-8. PubMed ID: 9397976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels.
    Rossini A; Gazzola GB; Ravaggi A; Agostinelli E; Biasi L; Albertini A; Radaeli E; Cariani E
    Transfusion; 1995 Feb; 35(2):108-11. PubMed ID: 7529954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjects positive for hepatitis C virus RNA with normal aminotransferase levels, a "trompe l'oeil" clinical picture?
    Morisco F; Leone D; Tuccillo C; Iasevoli P; Sessa G; De Luise G; De Dominicis R; Caporaso N
    Dig Liver Dis; 2000 Oct; 32(7):598-602. PubMed ID: 11142558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.
    Sumida Y; Nakashima T; Yoh T; Nakajima Y; Ishikawa H; Mitsuyoshi H; Sakamoto Y; Okanoue T; Kashima K; Nakamura H; Yodoi J
    J Hepatol; 2000 Oct; 33(4):616-22. PubMed ID: 11059866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hepatitis C virus (HCV) RNA: a reliable tool for evaluating HCV-related liver disease in anti-HCV-positive blood donors with persistently normal alanine aminotransferase values.
    Nalpas B; Romeo R; Pol S; Thiers V; Carnot F; Berthelot P; Brechot C
    Transfusion; 1995 Sep; 35(9):750-3. PubMed ID: 7570935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group.
    Shakil AO; Conry-Cantilena C; Alter HJ; Hayashi P; Kleiner DE; Tedeschi V; Krawczynski K; Conjeevaram HS; Sallie R; Di Bisceglie AM
    Ann Intern Med; 1995 Sep; 123(5):330-7. PubMed ID: 7542854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
    Hidaka I; Hino K; Korenaga M; Gondo T; Nishina S; Ando M; Okuda M; Sakaida I
    Liver Int; 2007 Aug; 27(6):845-53. PubMed ID: 17617128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis.
    Rossini A; Ravaggi A; Biasi L; Agostinelli E; Bercich L; Gazzola GB; Callea F; Radaeli E; Cariani E
    Hepatology; 1997 Oct; 26(4):1012-7. PubMed ID: 9328328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C.
    McCormick SE; Goodman ZD; Maydonovitch CL; Sjogren MH
    Am J Gastroenterol; 1996 Aug; 91(8):1516-22. PubMed ID: 8759653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.